FOXO4-DRI 10mg

Comprehensive Laboratory Profile

The acquisition of highly specific senolytic compounds is critical for institutional laboratories investigating cellular senescence and age-related tissue decline. The FOXO4-DRI 10mg peptide is a synthetically engineered D-retro-inverso analog designed to selectively interact with the FOXO4/p53 pathway.

Synthesized in the USA to the highest industry standards, this compound delivers the absolute analytical accuracy required by modern research facilities. Utilizing the FOXO4-DRI 10mg peptide ensures your facility obtains definitive data free from the inconsistencies often found in lower-purity research materials.

Biochemical Profile: FOXO4/p53 Modulation

FOXO4-DRI is a unique retro-inverso peptide designed to interfere with the interaction between the FOXO4 protein and the p53 tumor suppressor. In healthy cells, this interaction is minimal; however, in senescent cells, FOXO4 acts to sequester p53, thereby preventing it from initiating apoptosis (programmed cell death).

By introducing the FOXO4-DRI 10mg peptide into an in-vitro model, researchers can selectively displace p53 from FOXO4. This displacement allows p53 to relocate to the mitochondria, where it triggers the apoptotic cascade specifically within senescent cell populations.

Mechanism of Action

When introduced to cell cultures containing a population of senescent fibroblasts or other aging cell lines, the FOXO4-DRI 10mg compound functions as a senolytic agent. Senolytic compounds are uniquely valued for their ability to eliminate exhausted or damaged cells that accumulate during biological aging.

Researchers utilize this analog to study the clearance of these senescent cells and the subsequent reduction of the “senescence-associated secretory phenotype” (SASP). This allows for a more controlled evaluation of cellular regeneration and overall tissue metabolic health in a simulated aging environment.

Primary Research Applications

The specificity of this senolytic agent makes it a cornerstone tool for longevity, regenerative medicine, and oncology-related research.

Current scientific literature utilizes the FOXO4-DRI 10mg compound primarily for:

• Senolysis Assays: Investigating the clearance rates of p53-sequestered senescent cells.

• SASP Modulation Studies: Evaluating the reduction of inflammatory secretory profiles in aging cell cultures.

• Cellular Regeneration Modeling: Establishing control data for tissue recovery following the removal of senescent cell populations.

• p53-Pathway Mapping: Using the FOXO4-DRI 10mg peptide to evaluate the kinetic interactions between FOXO4 and p53 in high-stress models.

Purity and Quality Assurance

At Ion Peptides, we recognize that anomalous data from impure materials compromises research outcomes. Every batch of our FOXO4-DRI 10mg peptide is subjected to third-party analytical testing.

We utilize High-Performance Liquid Chromatography (HPLC) to verify a purity threshold of >99.0%. This ensures the complete isolation of the peptide from residual solvents or truncated sequences.

Furthermore, Mass Spectrometry (MS) is employed to verify the precise molecular weight. By securing your FOXO4-DRI 10mg supply through our USA synthesis network, you guarantee materials that meet the highest echelons of analytical compliance.

Storage and Reconstitution

The FOXO4-DRI 10mg vial is supplied as a lyophilized (freeze-dried) powder to ensure stability.

• Storage: Keep vials in a climate-controlled environment at or below -20°C. Protected from light and moisture, the powder remains stable for up to 36 months.

• Reconstitution: Utilize sterile bacteriostatic water.

  1. Allow the vial to reach room temperature before opening.

  2. Introduce the diluent slowly, letting it flow down the interior glass wall.

  3. Do not vortex or shake. Allow the FOXO4-DRI 10mg compound to dissolve via gentle, rotational swirling.

  4. Store reconstituted solution at 2°C to 8°C and utilize within standard laboratory protocol timelines.